Core Viewpoint - Zhendemedical has shown significant stock performance with a year-to-date increase of 269.26%, indicating strong market interest and potential growth in the medical supplies sector [1][2]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.184 billion yuan, reflecting a year-on-year growth of 1.88%. However, the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 25, Zhendemedical's stock price reached 78.80 yuan per share, with a market capitalization of 20.996 billion yuan. The stock experienced a net inflow of 26.7841 million yuan from major funds [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the latest appearance on November 17, where it recorded a net buy of 329,100 yuan [1]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period. The average number of circulating shares per shareholder decreased by 3.90% to 11,308 shares [2][3]. - Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 3.9382 million shares, which is an increase of 190,000 shares from the previous period [3].

《振德医疗关于第一期员工持股计划部分股份回购注销实施公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，振德医疗发布关于第一期员工持股计划部分股份回购注销实施公告。公告称，因第一期员工持股 计划第三个解锁期公司层面业绩考核未达标，公司决定回购注销未解锁股份615,667股，回购价格为 25.16元/股，资金来源为公司自有资金。本次回购注销已于2025年11月27日完成，公司总股本由 266,451,202股减少至265,835,535股。该事项不影响公司财务状况、经营成果及上市地位，不损害公司及 股东利益。 最新公告列表 截至2025年11月24日收盘，振德医疗（603301）报收于77.25元，较前一交易日上涨2.33%，最新总市值 为205.83亿元。该股当日开盘75.27元，最高77.29元，最低74.39元，成交额达4.91亿元，换手率为 2.42%。 ...

证券日报网讯 11月24日晚间，振德医疗发布公告称，鉴于公司第一期员工持股计划第三个解锁期公司 层面业绩考核指标未达成，对应的员工持股计划未能解锁的615，667股公司股份由公司进行回购注销。 注销日期：2025年11月27日。 （文章来源：证券日报） ...

证券代码：603301 证券简称：振德医疗 公告编号：2025-042 本次回购注销股份的有关情况： | 回购股份数量（股） | 注销股份数量（股） | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 615,667 | 615,667 | 2025 | 年 11 | 月 | 27 日 | 一、本次回购注销的决策与信息披露 1、公司分别于 2025 年 7 月 23 日、8 月 11 日召开第三届董事会 第二十二次会议、第三届监事会第十九次会议及 2025 年第一次临时 股东大会审议通过了《关于<公司第一期员工持股计划（草案修订稿） 及其摘要>的议案》、《关于<公司第一期员工持股计划管理办法（修订 稿）>的议案》、《关于回购公司第一期员工持股计划未解锁股份的议 案》、《关于变更部分回购股份用途并注销的议案》及《关于取消监事 会、变更公司注册资本、增加经营范围暨修订<公司章程>并办理工商 变更登记的议案》，同意将本员工持股计划未能解锁的 615,667 股公 司股份予以回购注销。具体内容详见公司于 2025 年 7 月 24 日在上海 证券交易所网站（w ...

Core Points - Zhendemedical (603301) closed at 75.49 yuan on November 21, 2025, down 14.79% from last week's 88.59 yuan [1] - The company's current market capitalization is 20.114 billion yuan, ranking 11th out of 126 in the medical device sector and 909th out of 5167 in the A-share market [1] Trading Information Summary - Zhendemedical was listed on the "Dragon and Tiger List" due to a price drop deviation of 7% on November 17, 2025, marking the first time in the last five trading days [1][3] Company Announcement Summary - Zhendemedical plans to engage in hedging activities related to polyethylene, polypropylene, and rubber to mitigate the impact of raw material price fluctuations on its operations. The maximum margin for this trading is set at 30 million yuan, with a maximum contract value of 200 million yuan, funded by the company's own resources. The trading period will last for 12 months from the date of board approval, which has already been granted without the need for shareholder meeting approval [1]

《振德医疗关于开展套期保值业务的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 近日，振德医疗发布关于开展套期保值业务的公告。公告称，公司拟开展聚乙烯、聚丙烯及橡胶等原材 料相关的金融衍生品套期保值业务，以降低原材料价格波动对公司经营的影响。交易保证金上限为 3,000万元，最高合约价值不超过20,000万元，资金来源为自有资金，交易期限自董事会审议通过之日起 12个月。该事项已获公司第四届董事会第四次会议审议通过，不需提交股东大会审议。公司指出，存在 市场、政策、履约、技术和操作等风险，并已制定相应风控措施。 最新公告列表 截至2025年11月20日收盘，振德医疗（603301）报收于77.0元，较前一交易日下跌1.8%，最新总市值为 205.17亿元。该股当日开盘78.8元，最高79.94元，最低76.76元，成交额达3.78亿元，换手率为1.83%。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 交易主要情况 证券代码：603301 证券简称：振德医疗 公告编号：2025-041 振德医疗用品股份有限公司 关于开展套期保值业务的公告 （二）交易金额 公司开展套期保值业务在授权期内任一时点保证金额度不超过人民币 3,000 万元，该额度可循环使用；任一时点持有的最高合约价值不超过人民币 20,000 万元。 | 交易目的 | □获取投资收益 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 套期保值（合约类别：商品；□外汇；□其他：________） □其他：________ | | | | | | | | | | | 交易品种 | 聚乙烯、聚丙烯及橡胶等原材料相关的金融衍生品 | | | | | | | | | | | 交易金额 | 预计动用的交易保证金和权利金上限（单位：万元） | | | | | | | | | 3, ...

Group 1 - The core point of the article highlights the recent decline in the stock price of Zhendemedical, which fell by 5.16% to 76.02 yuan per share, with a trading volume of 398 million yuan and a turnover rate of 1.91%, resulting in a total market capitalization of 20.256 billion yuan [1] - Zhendemedical, established on August 18, 1994, and listed on April 12, 2018, specializes in the production, research, and sales of medical dressings. The main revenue composition includes: surgical infection control 43.04%, basic care 20.46%, ostomy and modern wound care 18.59%, pressure treatment and fixation 10.75%, infection control protection 6.58%, and others 0.58% [1] Group 2 - From the perspective of major fund holdings, data shows that one fund under Jiashi Fund has a significant position in Zhendemedical. Jiashi New Tanghui Regular Mixed A (005088) held 10,200 shares in the third quarter, accounting for 1.03% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 42,200 yuan [2] - Jiashi New Tanghui Regular Mixed A (005088) was established on September 28, 2017, with a latest scale of 45.2371 million yuan. Year-to-date return is 14.94%, ranking 5064 out of 8140 in its category; the one-year return is 10.12%, ranking 5745 out of 8057; and since inception, it has incurred a loss of 5.7% [2]

Core Viewpoint - Zhendermedical (603301) experienced a significant decline of 9.52% in its stock price, with a trading volume of 8.33 billion yuan and a turnover rate of 3.79% on the day of reporting [2]. Trading Data - The stock was listed on the Shanghai Stock Exchange due to a daily price deviation of -9.06%, with net purchases from the Shanghai-Hong Kong Stock Connect amounting to 6.1894 million yuan [2]. - The top five trading departments accounted for a total transaction volume of 3.25 billion yuan, with a buying amount of 1.63 billion yuan and a selling amount of 1.62 billion yuan, resulting in a net purchase of 329,100 yuan [2]. - The largest buying and selling department was the Shanghai-Hong Kong Stock Connect, with buying and selling amounts of 64.4148 million yuan and 58.2254 million yuan, respectively [2]. Capital Flow - The stock saw a net outflow of 96.4244 million yuan in principal funds, with large orders contributing to a net outflow of 34.3331 million yuan and a net outflow of 62.0913 million yuan from major funds [2]. - Over the past five days, the net outflow of principal funds totaled 113 million yuan [2]. Financing and Margin Trading - As of November 14, the latest margin trading balance for the stock was 1.657 billion yuan, with a financing balance of 1.656 billion yuan and a securities lending balance of 1.2934 million yuan [2]. - Over the past five days, the financing balance increased by 172 million yuan, representing an increase of 11.59%, while the securities lending balance decreased by 254,700 yuan, reflecting a decline of 16.45% [2]. Financial Performance - In the third quarter report released on October 30, the company achieved a total revenue of 3.184 billion yuan, marking a year-on-year increase of 1.88%, while the net profit was 203 million yuan, showing a year-on-year decline of 33.91% [3].

Core Viewpoint - The stock of Zhendemedical (603301) has experienced a decline, with a closing price of 88.04 yuan on November 13, 2025, down by 2.93% from the previous day, indicating a negative trend in investor sentiment and market performance [1][2]. Financial Performance - For the first three quarters of 2025, Zhendemedical reported a main business revenue of 3.184 billion yuan, a year-on-year increase of 1.88%. However, the net profit attributable to shareholders was 203 million yuan, a decrease of 33.91% year-on-year [5]. - In Q3 2025, the company achieved a single-quarter main business revenue of 1.084 billion yuan, a slight increase of 0.1% year-on-year, but the net profit attributable to shareholders fell by 48.47% to 75.42 million yuan [5]. Market Activity - On November 13, 2025, the net outflow of main funds was 26.33 million yuan, accounting for 3.58% of the total transaction amount, while retail investors saw a net inflow of 48.40 million yuan, representing 6.59% of the total transaction amount [1][2]. - The financing balance on November 13, 2025, was 1.749 billion yuan, with a net repayment of 12.19 million yuan in financing [3]. Industry Comparison - Zhendemedical's total market capitalization is 23.458 billion yuan, significantly higher than the industry average of 11.676 billion yuan, ranking 9th out of 124 in the medical device industry [5]. - The company's net profit margin stands at 6.61%, below the industry average of 9.57%, indicating potential challenges in profitability compared to peers [5]. Stock Metrics - The price-to-earnings (P/E) ratio for Zhendemedical is 86.59, which is considerably higher than the industry average of 60.24, suggesting that the stock may be overvalued relative to its earnings [5]. - The gross margin for Zhendemedical is 33.93%, which is lower than the industry average of 51.22%, indicating less efficiency in cost management compared to competitors [5].